Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant.

Gabiria PastoreJacopo PolvereFabio FiorinoSimone LucchesiGiorgio MontesiIlaria RancanSara ZirpoliArianna LippiMiriam DuranteMassimiliano FabbianiMario TumbarelloFrancesca MontagnaniDonata MedagliniAnnalisa Ciabattini

Published in: Expert review of vaccines (2024)

Our data endorse the heterologous booster vaccination with mRNA as a valuable alternative to homologous schedules. This approach can serve as a solution in instances of formulation shortages and contribute to enhancing vaccine strategies for potential epidemics or pandemics.

Keyphrases

sars cov
dna repair
dna damage
randomized controlled trial
saccharomyces cerevisiae
binding protein
respiratory syndrome coronavirus
systematic review
electronic health record
drug delivery
big data
human health
coronavirus disease
gene therapy
infectious diseases
deep learning
artificial intelligence